

Enzo Biochem, Inc.

16:39 16 Oct 2018

Enzo Biochem shares slip after posting fiscal fourth-quarter loss of \$5.8m

Shares in Enzo Biochem (NYSE:ENZ) slipped Tuesday a day after the diagnostics and research company swung to a fiscal fourth quarter loss of \$5.8 million after breaking even in the year-ago quarter.

In the three months ended at the close of July, the New York-based company posted total revenue of \$24.5 million, which fell from \$28.2 million in the year-ago quarter. Its clinical services revenue, meanwhile, came in at \$16.8 million, down from \$20.4 million in the same period last year.

In the quarter, the company also reported that it received approval from the New York State Department of Health for an additional three women's health infectious disease diagnostic assays to expand its women's health panel to 16 pathogens on its AmpProbe platform.

The panel, which is performed using a single swab, now includes *Ureaplasma* spp./*M. genitalium*/*M. hominis* (UMM) in addition to *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Trichomonas vaginalis*, *Candida* spp (*C. albicans*, *C. glabrata*, *C. krusei*, *C. parapsilosis*, *C. tropicalis*), *Atopobium vaginae*, *Gardnerella vaginalis*, *Lactobacillus* spp, *Megasphaera* spp, and BVAB2.

READ: Enzo Biochem reports a wider-than-expected earnings loss due to decrease in service revenues

"Our focus is centered on providing cost efficient products and services utilizing our proprietary assays optimized for our automated, open system platforms that are compatible with existing sample collection devices as well as our own lower cost option," Enzo President Barry Weiner said in a statement.

"Besides the number of assays already approved, in process is the development of a screening assay for oncogenic forms of HPV, among others," Weiner added.

For the year, the company saw its loss widen to \$10.3 million, or \$0.22 per share while its revenue came in at \$104.7 million, down from \$107.8 million last year.

Its total legal expenses also climbed in the quarter to \$5.1 million compared to \$1.7 million in the year-ago quarter due partly to costs related to a patent infringement case.


Enzo Biochem shares slipped 5.3% on Tuesday to \$3.91.

Contact Ellen Kelleher at ellen@proactiveinvestors.com

Price: 2.23

Market Cap: \$106.05 m

1 Year Share Price Graph



February 2019 August 2019 February 2020

Share Information

Code: ENZ

Listing: NYSE

52 week	High	Low
	4.46	2.16

Sector: Medical technology & services

Website: www.enzo.com

Company Synopsis:

Enzo Biochem, Inc. (Enzo) is an integrated life sciences and biotechnology company focused on harnessing biological processes to develop research tools, diagnostics and therapeutics and serves as a provider of test services, including esoteric tests, to the medical community. The Company operates in three segments: Enzo Life Sciences, Enzo Clinical Labs and Enzo Therapeutics.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.